,i #aadth ,,congress #ast ,session ,h4 ,r4 #bdae ,,in ,,the ,,house ,,of ,,representatives ,may #ai1 #bjae ,mr4 ,burgess 7for himself and ,mr4 ,engel7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,federal ,food1 ,drug1 and ,cosmetic ,act to provide for establishment of a streamlined data review program4 #a4 ,streamlined data review program 7a7 ,in general ,chapter ,v of the ,federal ,food1 ,drug1 and ,cosmetic ,act is amended by inserting after section #eje;,f of such ,act 7#ba ,u4,s4,c4 #cee;f7 the following3 #eje;,f4 ,streamlined data review program 7a7 ,in general ,the ,secretary shall establish a streamlined data review program under which a holder of an approved application submitted under section #eje7;b77#a7 or under section #cea7;a7 of the ,public ,health ,service ,act may1 to support the approval or licensure 7as applicable7 of the use of the drug that is the subject of such approved application for a new qualified indication1 submit qualified data summaries4 7b7 ,eligibility ,in carrying out the streamlined data review program under subsection 7a71 the ,secretary may authorize the holder of the approved application to include one or more qualified data summaries described in subsection 7a7 in a supplemental application if-- 7#a7 the drug has been approved under section #eje7;c7 of this ,act or licensed under section #cea7;a7 of the ,public ,health ,service ,act for one or more indications1 and such approval or licensure remains in effect2 7#b7 the supplemental application is for approval or licensure 7as applicable7 under such section #eje7;c7 or #cea7;a7 of the use of the drug for a new qualified indication under such section #eje7;c7 or #cea7;a72 7#c7 there is an existing database acceptable to the ,secretary regarding the safety of the drug developed for one or more indications of the drug approved under such section #eje7;c7 or licensed under such section #cea7;a72 7#d7 the supplemental application incorporates or supplements the data submitted in the application for approval or licensure referred to in paragraph 7#a72 and 7#e7 the full data sets used to develop the qualified data summaries are submitted1 unless the ,secretary determines that the full data sets are not required4 7c7 ,public availability of information on program ,the ,secretary shall post on the public website of the ,food and ,drug ,administration and update annually-- 7#a7 the number of applications reviewed under the streamlined data review program2 7#b7 the average time for completion of review under the streamlined data review program versus other review of applications for new indications2 and 7#c7 the number of applications reviewed under the streamlined data review program for which the ,food and ,drug ,administration made use of full data sets in addition to the qualified data summary4 7d7 ,definitions ,in this section3 7#a7 ,the term qualified indication means-- 7,a7 an indication for the treatment of cancer1 as determined appropriate by the ,secretary2 or 7,b7 such other types of indications as the ,secretary determines to be subject to the streamlined data review program under this section4 7#b7 ,the term qualified data summary means a summary of clinical data intended to demonstrate safety and effectiveness with respect to a qualified indication for use of a drug4 4 7b7 ,sense of ,congress ,it is the sense of ,congress that the streamlined data review program under section #eje;,f of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a71 should enable the ,food and ,drug ,administration to make approval decisions for certain supplemental applications based on qualified data summaries 7as defined in such section #eje;,f74 7c7 ,guidance2 regulations ,the ,commissioner of ,food and ,drugs-- 7#a7 shall-- 7,a7 issue final guidance for implementation of the streamlined data review program established under section #eje;,f of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 as added by subsection 7a71 not later than #bd months after the date of enactment of this ,act2 and 7,b7 include in such guidance the process for expanding the types of indications to be subject to the streamlined data review program1 as authorized by section #eje;,f7c77#a77;,b7 of such ,act2 and 7#b7 in addition to issuing guidance under paragraph 7#a71 may issue such regulations as may be necessary for implementation of the program4